151 related articles for article (PubMed ID: 18661773)
21. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
22. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
23. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Leis JF; Primack SL; Schubach SE; Curtin PT; Druker BJ; Maziarz RT
Haematologica; 2004 Sep; 89(9):ECR30. PubMed ID: 15377482
[TBL] [Abstract][Full Text] [Related]
24. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
25. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
26. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
28. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
29. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J
Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
[TBL] [Abstract][Full Text] [Related]
30. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
31. Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia.
Aur RJ; Hanna M; Sabbah R; Sackey K; Willoughby S; Atwood J
Haematol Blood Transfus; 1990; 33():504-10. PubMed ID: 2323651
[No Abstract] [Full Text] [Related]
32. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
[TBL] [Abstract][Full Text] [Related]
34. Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Johnson NA; Fetni R; Caplan SN
Leuk Lymphoma; 2005 Apr; 46(4):629-30. PubMed ID: 16019496
[No Abstract] [Full Text] [Related]
35. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
[TBL] [Abstract][Full Text] [Related]
36. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
38. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Voglová J; Maisnar V; Beránek M; Chrobák L
Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
